Understanding prostate cancer risk in the use of 5-alpha reductase inhibitors
Authors
Teemu Murtola
Published Date
September 2017
DOI
https://doi.org/10.18591/BJUIK.0006
Updates
An updated version of this module was published in March 2025 https://doi.org/10.18591/BJUIK.0006.v2. If you are a BJUI Knowledge subscriber and would like to view the previous version please contact us.
Cookie preferences
This site makes use of cookies to help improve our understanding of how you use the site. This information does not directly identify you, but because we respect your right to privacy, you can choose not to allow some types of cookies.
